The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive.
Mayosi
B M
BM
Latouf
S E
SE
Commerford
P J
PJ
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000191:economics*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab